Treatment & prevention of osteoporosis in postmenopausal women. Osteoporosis in men. Treatment & prevention of glucocorticoid-induced osteoporosis in men & women. Paget's disease of bone in men & women.
Administer as IV infusion over no less than 15 min. Osteoporosis in postmenopausal women & in men 5 mg once a yr. Prevention of osteoporosis 5 mg given once every 2 yr. Treatment & prevention of glucocorticoid-induced osteoporosis 5 mg once a yr. Paget's disease 5 mg w/ infusion time not be <15 min given over a constant infusion rate. Patients w/ CrCl >35 mL/min 5 mg.
Renal impairment. Concomitant use w/ other drugs containing zoledronic or other biphosphonates. Treat preexisting hypocalcemia & mineral metabolism disturbances before initiation of therapy. Maintain Ca & vit D supplementation for serum Ca level maintenance. Monitor Ca & mineral levels. Withhold therapy if history or physical signs suggest dehydration, & until normovolemic status has been achieved & severe musculoskeletal pain occurs. Concomitant use w/ other nephrotoxic drugs. Osteonecrosis of the jaw may occur. Consider dental exam prior to therapy in patients w/ history of concomitant risk factors (eg, cancer, chemotherapy, RT, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). Avoid invasive dental procedures during treatment. Interrupt therapy if patient is presenting w/ an atypical femur fracture. Aspirin-sensitive patients. May affect ability to drive or use machines. Pregnancy & lactation. Elderly.
Sign Out
